Luciana Borio, MD (@llborio) 's Twitter Profile
Luciana Borio, MD

@llborio

Senior Fellow for Global Health CFR, fmr NSC Director for Medical & Biodefense Preparedness, fmr FDA Acting Chief Scientist (views are my own)

ID: 1270795052

linkhttp://www.archventure.com calendar_today15-03-2013 21:51:58

1,1K Tweet

11,11K Followers

474 Following

Robert Nelsen (@rtnarch) 's Twitter Profile Photo

In my 40 years of biotech, I was waiting to see this result. Never before have transplanted cells survived normal immune response without immunosuppression. Excited for patients, many whom I know see hope today for a possible cure for many diseases. globenewswire.com/news-release/2…

Luciana Borio, MD (@llborio) 's Twitter Profile Photo

The #H5N1 outbreak is very concerning despite assurances from public health officials. A novel flu virus for which humans have no background immunity is a formidable foe. Let’s hope the incoming team moves swiftly to build the array of required countermeasures.

Luciana Borio, MD (@llborio) 's Twitter Profile Photo

Excellent choice. Gerald Parker is experienced and clear-eyed about the threats we face. One of his favorite sayings is “let’s not wish the threat away.”

steve usdin (@steveusdin1) 's Twitter Profile Photo

NIH 2025 summer internships cancelled. This really sucks. NIH internships have launched many scientific careers. At a time when the U.S. is discouraging foreign students, how can it make sense to kill a program that costs pennies and is critical to building homegrown scientists?

steve usdin (@steveusdin1) 's Twitter Profile Photo

With ambiguous and scientifically unsupported statements on the Novavax COVID vaccine HHS, FDA have allowed politics to override public health. The consequences won't be limited to vaccines. biocentury.com/article/655774

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

Another window into points I made in this op ed yesterday, about Chinese biotech displacing U.S. innovation: China’s share of clinical trial starts dramatically increased — from 1% to 30% over last decade, and Chinese biotech companies are poised to overtake U.S. counterparts

Another window into points I made in this op ed yesterday, about Chinese biotech displacing U.S. innovation: 
China’s share of clinical trial starts dramatically increased — from 1% to 30% over last decade, and Chinese biotech companies are poised to overtake U.S. counterparts
Luciana Borio, MD (@llborio) 's Twitter Profile Photo

Good read from Vinay Prasad MD MPH & Marty Makary MD, MPH: nejm.org/doi/full/10.10… — Public trust in vax has fallen, driving hesitancy even around proven shots like MMR, long established as safe & highly effective.

Luciana Borio, MD (@llborio) 's Twitter Profile Photo

“There are new cures for cancer that need to be uncovered, new discoveries waiting to be made, more lives to be saved that previously were unsavable. This will happen when truth is prioritized, when science is protected, and when people come first.” Prof Odunsi

Luciana Borio, MD (@llborio) 's Twitter Profile Photo

Stirring up good trouble at #BIO2025 with the brilliant Esper Kallas of Instituto Butantan — the powerhouse driving vaccine innovation for Brazil, Latin America, and the world.

Stirring up good trouble at #BIO2025 with the brilliant <a href="/ekallas/">Esper Kallas</a> of <a href="/butantanoficial/">Instituto Butantan</a> — the powerhouse driving vaccine innovation for Brazil, Latin America, and the world.